Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649359 · ClinicalTrials.gov registry record · Phase 2
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
A Phase 2 study of Multiple Myeloma, sponsored by Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT04649359 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 187 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04649359, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Conditions Studied
Interventions
- DRUG Elranatamab (PF-06863135)
Study Locations (20)
California
- Beverly Hills Cancer Center - Beverly Hills
- The Regents of the University of California - Irvine
- Ronald Reagan UCLA Medical Center Drug information Center - Los Angeles
- The Regents of the University of California - Los Angeles
- UCLA Hematology/Oncology Clinic - Los Angeles
- UCLA Ronald Reagan Medical Center - Los Angeles
- UC Irvine Health - Chao Family Comprehensive Cancer Center - Orange
Georgia
- Winship Cancer Institute @ Emory University Hospital Midtown - Atlanta
- Emory University Hospital - Atlanta
- Emory University - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
- Blood and Marrow Transplant Group of Georgia - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
- Northside Hospital - Atlanta
Illinois
- Northwestern Medical Group - Chicago
- Northwestern Memorial Hospital - Chicago
- Loyola University Chicago performing research at Loyola University Medical Center - Maywood
- Loyola University Medical Center - Maywood
Florida
- Baptist Hospital of Miami - Miami
Indiana
- Indiana Blood and Marrow Transplantation - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2021-02-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04649359
The ClinicalTrials.gov registry entry for NCT04649359 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (66% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab (PF-06863135) is the first listed.
NCT04649359 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT04649359 about?
NCT04649359 is a clinical study titled "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb". The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma c...
What is the current status of trial NCT04649359?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2021-02-02. Estimated completion is 2026-12-31.
What conditions does trial NCT04649359 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04649359?
The interventions under investigation include: Elranatamab (PF-06863135) (DRUG).
Who is sponsoring clinical trial NCT04649359?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04649359 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.